Report Highlights
The global market for botanical and plant-derived drugs will grow from $29.4 billion in 2017 to around $39.6 billion by 2022 with a compound annual growth rate (CAGR) of 6.1% for the period of 2017-2022.
Report Includes
- An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
- Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address specific medical conditions or symptoms)
- Examination of the industry structure, competition, and market drivers
- Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry
Report Scope
This report is an analytical business tool whose primary purpose is to describe the botanical drug industry with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.
For the purposes of this report, botanicals are those drugs that are FDA-approved under the botanical drug pathway, while plant-derived drugs are both botanicals as well as other approved drugs that contain a mixture of natural plant-derived and synthetic or semisynthetic substances.
The study’s main focus is on legal, prescription-required therapeutic medicines sold in the open market. The study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms). While there is a substantial market for these products, the medical value of many of these substances has not been demonstrated conclusively.
The study also does not cover the following:
- Underground or illicit drugs.
- Home remedies.
- Tribal medicines.
- Drugs derived from Archaea, bacteria and fungi (molds and yeasts).
- Nonmedicinal plant substances, such as laxative cellulose and pectin fiber.
- Intravenously delivered nutrients of plant origin, such as dextrose.
- Plant-derived substances serving as pharmaceutical excipients, such as starch, methylcellulose, guar gum, vegetable oils, fatty acids, cocoa butter and candelilla wax.
- Plant substances serving in cosmetics, toiletries and personal care products.
- Microbial fermentation products, even those made with culture media incorporating corn steep liquor, starch or other plant-derived nutrients.
- Marine life.
The format of the study is organized around the following topics:
- Major types and applications of botanical drugs with plant-derived drugs as their backdrop.
- Industry structure.
- Market size and segmentation, including the breakdown of sales by therapeutic area and geographic area.
- Market drivers.
- Market projections through 2022.
- Competition.
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry.
Analyst Credentials
Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature and an M.A. in management from Harvard University's extension program. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm (in the Research Triangle Park area of North Carolina) that focused on pharmaceuticals and biotechnology. Before joining that firm, she published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.
Report Highlights
The global market for botanical and plant-derived drugs was valued at $23.2 billion in 2013 and $24.4 billion in 2014. This total market is expected to reach $25.6 billion in 2015 and nearly $35.4 billion in 2020, with a compound annual growth rate (CAGR) of 6.6% from 2015 to 2020.
Report Includes
- An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward.
- Analyses of global market trends, with data from 2013 and 2014, estimates for 2015, and projections of CAGRs through 2020.
- A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms).
- Examination of the industry structure, competition, and market drivers.
- Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area.
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry.
Report Highlights
The global botanical and plant-derived drug market was valued at $21.4 billion in 2011 and should reach $22.1 billion in 2012. Total market value is expected to reach $26.6 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 3.7%.
Report Includes
- An overview of the botanical drug industry, with the overall plant-derived drug industry as a backdrop and the global market for these drugs going forward
- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
- A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally sold as dietary supplements (i.e., to promote overall “wellness” rather than to address a specific medical condition or symptoms)
- Examination of the industry structure, competition, and market drivers
- Discussion of market size and segmentation, including breakdowns of sales by therapeutic area and geographic area
- Observations and conclusions regarding the future of the botanical and plant-derived drug industry
- Comprehensive company profiles of major players.
Report Highlights
-
The global market for botanical and plant-derived drugs is expected to increase from $19.5 billion in 2008 to $32.9 billion in 2013, a compound annual growth rate (CAGR) of 11.0%.
-
Botanical drugs generated $127,000.0 in 2008. This segment should reach $2.4 billion in 2013 for a CAGR of 651.7%.
-
All other plant derived drugs generated $19.5 billion in 2008. This is expected to reach $30.5 billion in 2013, for a CAGR of 9.4%.
Report Highlights
-
The global market for plant-derived drugs was worth an estimated $18 billion in 2005. BCC expects this figure to grow to nearly $19 billion in 2006 and more than $26 billion by 2011, at an AAGR of 6.6% between 2006 and 2011.
-
Cancer treatment is expected to become the largest application of plant-derived drugs by 2011, with 24% of the market.
-
Respiratory problems such as asthma represent the largest medical application of plant-derived drugs in 2005, accounting for 26% of total sales of plant-derived drugs.
-
The North American market (the U.S. and Canada) accounts for over half of the world market for plant-derived drugs, and is projected to increase faster than either the Western European or developed Asian regional markets, exceeding 54% of the global market by 2011
Report Highlights
-
Total worldwide sales of plant-derived drugs in 2002 are estimated at $13.7 billion.
-
Sales are projected to increase at an average annual growth rate (AAGR) of 6.4% through 2007.
-
The U.S. accounts for 50% of the global plant-derived drug market.
-
The U.S. market will grow faster than foreign markets as a whole, at an AAGR of 7.5% per year vs. 5.3%.
Related Reports
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Global Markets for Generic Drugs
The global market for generic drugs is expected to grow from $435.3 billion in 2023 and projected to reach $655.8 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.5% from 2023 to 2028.
Global Herbal Medicine Market
The global market for herbal medicine is expected to increase from $169.1 billion in 2023 to $279.8 billion by the end of 2028, with a compound annual growth rate (CAGR) of 10.6% during the forecast period of 2023-2028.
Biological Therapies for Cancer: Technologies and Global Markets
The global cancer biologics market should reach $143.0 billion by 2026 from $77.5 billion in 2021 at a compound annual growth rate (CAGR) of 13.0% for the forecast period of 2021 to 2026.
Recent Reports
Companion Diagnostics: Technologies and Markets
The global market for companion diagnostics is estimated to increase from $7.6 billion in 2023 to reach $15.4 billion by 2028, at a compound annual growth rate (CAGR) of 15.2% from 2023 through 2028.
Exosome Diagnostics, Therapeutics and Research Tools: Global Markets
The global market for exosome diagnostics, therapeutics and research tools is estimated to increase from $227.5 million in 2023 to reach $1.3 billion by 2028, at a compound annual growth rate (CAGR) of 42.2% from 2023 through 2028.
Peptide Synthesis: Global Markets
The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.8% during the forecast period of 2023 to 2028.
Oligonucleotides: Global Markets
The global market for oligonucleotides is expected to grow from $7.0 billion in 2023 and projected to reach $11.7 billion by the end of 2028, at a compound annual growth rate (CAGR) of 11.0% during the forecast period of 2023 to 2028.
Global Market for Cell and Gene Therapy
The global market for cell and gene therapy is expected to grow from $7.2 billion in 2023 and projected to reach $23.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 26.4% during the forecast period of 2023 to 2028.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
ESG Trends in Chemical Industry
This report focuses on the ESG trends in the chemical industry and evaluates the ESG implementation including current and future potential. The report utilizes various databases, including sustainability reports, annual reports, and other indicators used to develop the current market. The study provides detailed information on the main factors influencing ESG growth in the chemical industry. It enables the reader to understand the industry in general while also providing insight into the inter-relationship between ESG and the sustainable chemical industry. The report describes market growth, developing trends, industry leaders, and applications of ESG implementation in the chemical industry.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Smartphone-Based Patient Monitoring: Global Market
The global smartphone-based patient monitoring market should reach $21.5 billion by 2027 from $6.8 billion in 2022 at a compound annual growth rate (CAGR) of 25.9% for the forecast period of 2022 to 2027.
Seawater and Brackish Water Desalination
The global market for seawater and brackish water desalination is estimated to increase from $14.7 billion in 2022 to $21.7 billion by 2027, at a compound annual growth rate (CAGR) of 8.1% from 2022 through 2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More